Review
Open access
Aug 2026
Evolving pharmacotherapy in Alzheimer’s disease: from symptomatic management to disease modification-A PRISMA 2020-guided narrative review
Overall, symptomatic therapies continue to represent the foundation of AD management, whereas anti-amyloid monoclonal antibodies mark an important, although incremental, transition toward disease modification in carefully selected patients.
Najish Parveen, J. Ansari, Manvi Singh et al.
· The Egyptian Journal of Neur... · 0 citations